miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 5, 2026

Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin

View original at seekingalpha.com
Samsara projects FY 2027 revenue of $2.005B-$2.013B while targeting 20% non-GAAP operating margin Earnings Call Insights: Samsara (IOT) Q1 fiscal 2027 MANAGEMENT VIEW * "Samsara delivered a strong start to FY '27, with another quarter of durable and efficient growth" (CEO Sanjit Biswas), including: "We ended Q1 with ne…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Memory market visibility isn't as good as it has been in the past

    60% confidence
  • GAAP EPS would still be positive excluding the Motive arbitration award

    60% confidence
  • Maintenance is just where Samsara is going to start with Hertz

    60% confidence
  • Nothing about Q1 strength stands out as one-time in nature

    60% confidence
  • $100,000-plus customers represent 62% of total ARR

    60% confidence
  • Free cash flow margin was 15%

    60% confidence
  • 18% of net new ACV came from non-U.S. geographies, tied for a quarterly record

    60% confidence
  • Samsara hasn't had a problem stocking component supply despite tighter memory markets

    60% confidence
  • Q2 non-GAAP operating margin expected to be 18%

    60% confidence
  • Samsara's guidance philosophy remains the same and is de-risked for potential downside scenarios

    60% confidence
  • The Supreme Court ruling on broker liability likely leads to heightened focus on road safety

    60% confidence
  • Q1 was the strongest international quarter Samsara has had

    60% confidence
  • Samsara also expects to be GAAP profitable for full year FY '27

    60% confidence
  • Emerging products contributed more than 20% of net new ACV for the second consecutive quarter

    60% confidence
  • Net new ARR over the last 12 months was $455 million

    60% confidence
  • Samsara is spending more money on AI and cloud, pressuring gross margin

    60% confidence
  • Large enterprise deal cycles can take multiple quarters

    60% confidence
  • Samsara has confidence it will be able to find the supply it needs

    60% confidence
  • In May, Samsara gathered hundreds of public sector customers at Go Beyond event in Chicago, introducing Waste Intelligence, Ground Intelligence, and Ridership Management

    60% confidence
  • Waste Intelligence is monetized as additional SKUs

    60% confidence
  • Samsara expects to be GAAP profitable for Q2

    60% confidence
  • At some point Samsara may offer a consumption-based pricing model for agents

    60% confidence
  • Samsara signed 11 $1 million-plus net new ACV transactions in Q1

    60% confidence
  • For Q2, Samsara expects revenue between $482 million and $484 million

    60% confidence
  • The full-year guide raise is almost double the amount of the Q1 beat

    60% confidence
  • Samsara is emphasizing LTM (last 12 months) figures to reduce perceived volatility from large deal timing

    60% confidence
  • Q1 net new ARR was $101 million

    60% confidence
  • Samsara added $101 million in net new ARR in Q1

    60% confidence
  • GAAP EPS included a $30 million arbitration award from one of Samsara's lawsuits against Motive

    60% confidence
  • Europe contributed a record amount of net new ACV mix

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com